🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Zimmer Biomet Holdings, Inc. ZBH SPX

Healthcare · Medical Devices · United States
https://www.zimmerbiomet.com

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

READ MORE ›
$82.33
-9.74% 1Y

Market & Price

Market Cap
$15.93B
Current Price
$82.33
High / Low (52W)
$106.87 / $79.58
Beta
0.47

Valuation

Stock P/E
21.33
Industry PE
23.65
Forward P/E
9.14
PEG Ratio
0.59
Book Value
$65.53
Price to Book
1.26
P/S
1.89
EV/EBITDA
8.93
Dividend Yield
1.17%

Profitability & Returns

ROCE
5.48%
ROE
6.07%
ROA
4.10%
Profit Margin
9.05%
Op Margin
19.69%
EPS (Latest Qtr)
$1.22
EPS (TTM)
$3.86

Balance Sheet & Liquidity

Debt/Equity
0.60
Quick Ratio
0.77
Current Ratio
1.73
Debt
$7.59B
Total Assets
$23.09B
Current Assets
$5.12B
Working Capital
$2.54B

Ownership

Promoter Holding
0.20%
Chg in Prom Hold
-
FII / Inst Holding
103.50%
Chg in FII Hold
-0.01%

Financial Snapshot

Enterprise Value
$23.04B
Total Revenue (TTM)
$8.41B
EBITDA
$2.58B
Free Cash Flow
$1.04B
Operating Cash Flow
$1.67B
Shares Outstanding
193.46M
Gross Margin
70.18%
Payout Ratio
24.87%

Growth (CAGR)

Revenue 5Y
5.85%
Profit 5Y
44.98%
Revenue (YoY)
9.30%
Earnings (YoY)
34.10%

PROS

  • Profit CAGR of 45.0% over 5 years.
  • Generates positive free cash flow.

CONS

  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ZBH Zimmer Biomet Holdings, Inc. SPX 82.33 21.33 $15.93B 1.17% 5.48% 6.07% 5.85% 44.98%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue ------1.97B1.95B1.81B2.07B2.02B2.01B1.84B2.07B1.98B1.99B1.89B2.13B1.78B1.23B1.93B2.09B1.60B1.76B1.69B1.66B1.78B1.67B1.83B1.87B1.75B1.89B1.94B1.82B-1.91B2.08B2.00B2.24B2.09B
Cost of Revenue -----------------------------------549.80M592.20M559.30M792.40M576.20M
Gross Profit 1.09B1.10B1.14B1.16B1.19B1.25B1.31B1.27B1.16B1.33B1.29B1.27B1.16B1.34B1.28B1.26B1.21B1.40B1.15B653.90M1.21B1.29B-------------1.36B1.49B1.44B1.45B1.51B
Operating Expenses -----------------------------------1.02B1.09B1.10B1.17B1.12B
Operating Income 116.00M-245.50M201.60M195.50M-348.10M280.10M211.20M-305.00M296.00M223.30M-350.20M204.70M245.80M--456.00M-171.70M299.20M-258.70M224.80M243.00M198.40M280.90M245.30M327.30M329.60M266.60M265.90M351.30M279.50M-338.90M396.40M338.30M282.60M395.10M
EBITDA -----------------------------------549.60M575.70M638.20M453.90M640.10M
Interest Expense -----------------------------------66.20M79.30M75.40M71.90M68.80M
Pretax Income -----------------------------------229.00M224.60M279.20M98.00M301.30M
Tax Provision -----------------------------------46.50M71.20M48.00M-39.90M63.00M
Net Income 22.20M127.00M108.80M-31.30M158.80M69.60M299.40M184.20M98.80M1.23B174.70M185.00M162.20M-901.10M246.10M133.70M431.10M320.70M-508.50M-206.60M242.50M333.70M198.10M141.90M145.60M14.20M153.70M194.00M232.50M209.60M162.70M172.40M242.80M249.10M-182.00M152.80M230.90M139.30M238.10M
Diluted EPS 0.110.620.54-0.160.780.341.470.900.486.030.850.900.79-4.421.200.652.081.54-2.46-1.001.161.590.940.670.690.070.730.921.111.000.770.841.181.231.200.910.771.16-1.22

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue ---------7.67B7.80B7.93B7.98B6.13B-6.94B7.39B7.68B8.23B
Cost of Revenue ---------------2.02B2.08B2.19B2.49B
Gross Profit 3.02B3.12B3.10B3.21B3.33B3.35B3.34B3.42B-------4.92B5.31B5.49B5.74B
Operating Expenses ---------------3.73B3.86B3.96B4.38B
Operating Income 1.13B1.09B1.02B916.70M1.02B1.05B1.07B1.04B467.30M821.10M799.30M33.80M1.14B83.10M-1.19B1.45B1.53B1.36B
EBITDA ---------------1.49B2.22B2.25B2.22B
Interest Expense ---------------164.80M201.20M218.00M292.80M
Pretax Income ---------------403.50M1.07B1.04B830.80M
Tax Provision ---------------112.30M42.20M131.40M125.70M
Net Income 773.20M848.60M717.40M596.90M760.80M755.00M780.40M720.30M147.00M305.90M1.81B-379.20M1.13B-138.90M-231.40M1.02B903.80M705.10M
Diluted EPS 3.263.723.322.974.034.294.544.200.771.518.90-1.865.47-0.67-1.104.884.433.55
R&D Expense ---218.50M238.40M225.60M-------------

Compounded Sales Growth

5 Years:5.85%
1 Year:9.30%

Compounded Profit Growth

5 Years:44.98%
1 Year:34.10%

Stock Price Performance

1 Year:-9.74%
6 Months:-14.73%
3 Months:-16.14%
1 Month:+2.82%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Jun 2021Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --7.24B7.79B8.00B8.52B9.01B9.60B9.66B27.16B26.68B26.01B24.13B24.64B24.42B--21.07B21.50B21.37B23.09B
Current Assets -----------------4.43B4.61B4.67B5.12B
Cash & Equivalents 265.70M463.90M212.60M691.70M668.90M768.30M884.30M1.08B1.08B1.46B634.10M524.40M542.80M617.90M802.10M--375.70M415.80M525.50M591.90M
Inventory -----------------2.15B2.39B2.24B2.29B
Receivables -----------------1.38B1.44B1.48B1.70B
Total Liabilities --1.59B2.15B2.23B3.00B3.15B3.28B3.11B17.27B17.01B14.28B12.85B12.25B12.22B--9.04B9.01B8.89B10.39B
Current Liabilities --771.10M690.70M702.50M867.10M866.00M1.03B1.02B1.62B2.38B3.07B2.42B3.44B2.56B--2.36B2.86B2.45B2.58B
Long Term Debt --460.10M1.13B1.14B1.58B1.72B1.67B1.43B11.50B10.67B8.92B8.41B6.72B7.63B1.00B-5.15B4.87B5.34B6.93B
Total Debt -----------------5.70B5.77B6.20B7.52B
Total Equity --5.65B5.64B5.77B5.51B5.86B6.30B6.55B9.89B9.67B11.74B11.27B12.39B12.19B--12.02B12.48B12.47B12.70B
Shares Outstanding -----------------313.80M316.20M317.47M318.68M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 1.08B1.04B1.12B1.19B1.18B1.15B963.10M--1.63B1.58B1.75B1.59B1.20B-1.28B1.58B1.50B1.70B
Investing Cash Flow -491.50M-924.20M-381.20M-726.90M-624.40M-592.10M-282.50M---1.69B-510.80M-416.60M-729.30M-613.80M--529.20M-778.90M-888.10M-1.98B
Financing Cash Flow -399.50M-343.50M-262.10M-489.60M-455.80M-436.50M-467.30M---743.20M-1.21B-1.30B-779.90M-421.80M--843.80M-763.50M-484.50M326.00M
Capital Expenditure -192.70M-250.00M-105.10M-79.20M-113.80M-114.70M-100.00M-144.90M-167.70M-184.70M-156.00M-162.70M-207.10M-111.90M--217.60M-394.50M-356.80M-276.90M
Free Cash Flow 891.70M788.10M1.01B1.11B1.06B1.04B863.10M--1.45B1.43B1.58B1.38B1.09B-1.07B1.19B1.14B1.42B
Net Change in Cash ----------------88.30M39.20M126.80M47.40M
Share Buybacks 576.30M737.00M923.70M505.60M1.05B485.60M720.80M400.90M150.00M415.50M-----126.40M692.20M868.00M487.00M

Ratios (Annual)

Figures in %.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ---------------70.9%71.8%71.5%69.7%
Operating Margin % ---------10.7%10.2%0.4%14.3%1.4%-17.2%19.6%19.9%16.5%
Net Margin % ---------4.0%23.2%-4.8%14.2%-2.3%-3.3%13.8%11.8%8.6%
ROE % -15.0%12.7%10.3%13.8%12.9%12.4%11.0%1.5%3.2%15.5%-3.4%9.1%-1.1%-1.9%8.2%7.2%5.6%
ROCE % -16.9%14.4%12.6%13.4%12.9%12.5%12.0%1.8%3.4%3.5%0.2%5.4%0.4%-6.4%7.8%8.1%6.6%

Shareholding Pattern

Insiders
0.20%
Institutions
103.50%
Public Float
103.70%

Top Institutional Holders

#Holder% HeldSharesValue
1 Dodge & Cox Inc. 12.17% 23.54M $1.94B
2 Blackrock Inc. 7.93% 15.34M $1.26B
3 Harris Associates L.P. 6.70% 12.96M $1.07B
4 Vanguard Capital Management LLC 6.61% 12.79M $1.05B
5 Capital International Investors 4.71% 9.12M $750.79M
6 State Street Corporation 4.56% 8.83M $726.57M
7 Vanguard Portfolio Management LLC 4.47% 8.65M $712.17M
8 Price (T.Rowe) Associates Inc 4.14% 8.00M $658.62M
9 Franklin Resources, Inc. 2.82% 5.45M $448.92M
10 Geode Capital Management, LLC 2.78% 5.38M $442.90M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ZBH

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks